A life sciences company

​

​

Focused on the research & development of Psilocybin

based medical & nutraceutical products

The world of Psilocybin

Psilocybin

Psilocybin is a naturally occurring psychedelic  compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain.

​

Studies

Preliminary studies from institutions like Imperial College of London, University of Zurich, Johns Hopkins, NYU and UCLA, suggest that psilocybin-assisted therapy could be a revolutionary treatment for depression and addiction.  The FDA has already granted "breakthrough therapy" status to study psilocybin-assisted treatment for treatment-resistant depression.

RegulatoryOutlook

Psilocybin is legal in the Netherlands, Jamaica, Brazil and Samoa. However just this year the State of Colorado voted in favor of Initiative 301, which resulted in Denver becoming the first US city to decriminalize psilocybin. Several weeks later, Oakland, California followed Denver and now Oregon is trying to get a similar measure on the ballot for 2020.

Psilocybin

Pharmacodynamics

Psilocybin is rapidly dephosphorylated in the body to psilocin, which is a partial agonist for several serotonin receptors, which are also known as 5-hydroxytryptamine (5-HT) receptors. Psilocin has a high affinity for the 5-HT2B and 5-HT2C receptors in the human brain, and with a slightly lower affinity for the 5-HT2A receptor.

​

Psilocin binds with low affinity to 5-HT1 receptors, including 5-HT1A and 5-HT1D. Various lines of evidence have shown that interactions with non-5-HT2 receptors also contribute to the subjective and behavioral effects of the chemical. For example, psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia.

​

Serotonin receptors are located in numerous parts of the brain, including the cerebral cortex, and are involved in a wide range of functions, including regulation of mood and motivation.

About

Cybin Corp

Cybin Corp is advancing psilocybin research and IP for the medical  and nutraceutical sectors.  We are focused on becoming one of the first company’s in the world to simultaneously launch psilocybin medical and nutraceutical trials and products into a 100% legal jurisdiction where vast infrastructure is  already in place through our partners for clinical trials and product development.

​

The company is lead by an experienced team who has run over 200 clinical trials and has successfully brought multiple new drug indications to market.

​

We have a clear strategy to advance medical clinical trials and IP around indications such as depression, addiction and eating disorders which collectively affect over 760M people globally.

​

Our nutraceutical product strategy focuses on key jurisdictions where non hallucinogenic micro-dose products can be clinically tested for safety and efficacy and can be sold to the general public for brain health and cognitive enhancement. 

​

​

Contact Us

Have questions?